{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:46:11Z","timestamp":1790127971435,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd002277.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T00:00:00Z","timestamp":1355270400000}}],"reference-count":51,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002277.pub4","type":"journal-article","created":{"date-parts":[[2012,12,6]],"date-time":"2012-12-06T23:49:33Z","timestamp":1354837773000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Intravenous immunoglobulin for myasthenia gravis"],"prefix":"10.1002","volume":"2012","author":[{"given":"Philippe","family":"Gajdos","sequence":"first","affiliation":[{"name":"Hopital Raymond Poincar\u00e9 (APHP); Service de R\u00e9animation; 104, Boulevard Raymond Poincar\u00e9 92380 Garches Ile de France France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Chevret","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Louis; Departement de Biostatistique et Informatique M\u00e9dicale; 1 Avenue Claude Vellefaux 75475 Paris France Cedex 10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus V","family":"Toyka","sequence":"additional","affiliation":[{"name":"University of W\u00fcrzburg; Neurology; Josef-Schneider-Str.11 W\u00fcrzburg Bavaria Germany 97080"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,12,12]]},"reference":[{"issue":"23","key":"10.1002\/14651858.CD002277.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD002277.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD002277.pub4-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Gajdos P Tranchant C Clair B Bolgert F Eymard B Stojkovic T Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial Archives of Neurology 2005 1689 93","DOI":"10.1001\/archneur.62.11.1689"},{"issue":"12","key":"10.1002\/14651858.CD002277.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","article-title":"Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis","volume":"25","author":"Ronager","year":"2001","journal-title":"Artificial Organs"},{"key":"10.1002\/14651858.CD002277.pub4-BIB0005|cit5","unstructured":"Schuchardt V Kohler W Hund E Scheglmann K Fleisher E Jung K A randomized controlled trial of high dose intravenous immunoglobulin versus methylprednisolone in myasthenia gravis. An interim analysis. 2002 Data on file"},{"issue":"4","key":"10.1002\/14651858.CD002277.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mus.10224","article-title":"Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis","volume":"26","author":"Wolfe","year":"2002","journal-title":"Muscle and Nerve"},{"issue":"11","key":"10.1002\/14651858.CD002277.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis. A randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002277.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","article-title":"Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis","volume":"14","author":"Liu","year":"2009","journal-title":"Therapeutic Apheresis and Dialysis"},{"issue":"4","key":"10.1002\/14651858.CD002277.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<551::AID-MUS14>3.0.CO;2-O","article-title":"Immunoglobulin treatment in refractory myasthenia gravis","volume":"23","author":"Achiron","year":"2000","journal-title":"Muscle & Nerve"},{"issue":"7","key":"10.1002\/14651858.CD002277.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1001\/archinte.1986.00360190143020","article-title":"High dose intravenous immunoglobulin in the management of myasthenia gravis","volume":"146","author":"Arsura","year":"1986","journal-title":"Archives of Internal Medicine"},{"issue":"2 Pt 2","key":"10.1002\/14651858.CD002277.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1016\/0090-1229(89)90083-4","article-title":"Experience with intravenous immunoglobulin in myasthenia gravis","volume":"53","author":"Arsura","year":"1989","journal-title":"Clinical Immunology and Immunopathology"},{"issue":"10","key":"10.1002\/14651858.CD002277.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1212\/WNL.33.10.1316","article-title":"Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity","volume":"33","author":"Besinger","year":"1983","journal-title":"Neurology"},{"issue":"8924","key":"10.1002\/14651858.CD002277.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0140-6736(94)92205-5","article-title":"Randomised trial of intravenous immunoglobulin G, intravenous anti-D and oral prednisone in childhood acute immune thrombocytopenic purpura","volume":"344","author":"Blanchette","year":"1994","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD002277.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ana.10205","article-title":"Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome","volume":"51","author":"Buchwald","year":"2002","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD002277.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mus.20269","article-title":"Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins","volume":"31","author":"Buchwald","year":"2005","journal-title":"Muscle and Nerve"},{"issue":"2","key":"10.1002\/14651858.CD002277.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-0404.1991.tb04912.x","article-title":"Treatment of myasthenia gravis with high-dose intravenous immunoglobulin","volume":"84","author":"Cosi","year":"1991","journal-title":"Acta Neurologica Scandinavica"},{"issue":"27","key":"10.1002\/14651858.CD002277.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD002277.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B","article-title":"Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines","volume":"22","author":"Dalakas","year":"1999","journal-title":"Muscle and Nerve"},{"issue":"21","key":"10.1002\/14651858.CD002277.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJM197711242972102","article-title":"Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis","volume":"297","author":"Dau","year":"1977","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002277.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJM199201093260206","article-title":"Manipulating the immune system with immune globulin","volume":"326","author":"Dwyer","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"8381","key":"10.1002\/14651858.CD002277.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(84)92294-3","article-title":"High dose intravenous gammaglobulin for myasthenia gravis","volume":"1","author":"Fateh-Moghadam","year":"1984","journal-title":"Lancet"},{"issue":"15","key":"10.1002\/14651858.CD002277.pub4-BIB0022|cit22","first-page":"939","article-title":"Long term effects of plasma exchange in myasthenia gravis. Results from a randomised study","volume":"12","author":"Gajdos","year":"1983","journal-title":"Presse M\u00e9dicale"},{"issue":"8373","key":"10.1002\/14651858.CD002277.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0140-6736(84)90469-0","article-title":"High dose intravenous gammaglobulin for myasthenia gravis","volume":"1","author":"Gajdos","year":"1984","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002277.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1749-6632.1987.tb51387.x","article-title":"High dose intravenous gamma globulin for myasthenia gravis: an alternative to plasma exchange","volume":"505","author":"Gajdos","year":"1987","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"4","key":"10.1002\/14651858.CD002277.pub4-BIB0025|cit25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002275","article-title":"Plasma exchange for generalised myasthenia gravis","author":"Gajdos","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD002277.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood.V82.5.1415.bloodjournal8251415","article-title":"Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high dose intravenous immunoglobulin","volume":"82","author":"Godeau","year":"1993","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002277.pub4-BIB0027|cit27","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"3","key":"10.1002\/14651858.CD002277.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00002826-200105000-00010","article-title":"The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis","volume":"24","author":"Hilkevich","year":"2001","journal-title":"Clinical Neurophamacology"},{"key":"10.1002\/14651858.CD002277.pub4-BIB0029|cit29","unstructured":"Hohlfeld R Melms A Toyka KV Drachman DB Neurological disorders: course and treatment San Diego, CA Academic Press 1996 947 64"},{"issue":"8232","key":"10.1002\/14651858.CD002277.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD002277.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD002277.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/CND.0b013e3181660807","article-title":"A comparision of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis","volume":"9","author":"Jensen","year":"2008","journal-title":"Journal of Clinical Neuromuscular Disease"},{"issue":"8","key":"10.1002\/14651858.CD002277.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/archneur.1981.00510080040003","article-title":"Plasmapheresis in refractory generalized myasthenia gravis","volume":"38","author":"Kornfeld","year":"1981","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD002277.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Annals of Neurology"},{"issue":"8114","key":"10.1002\/14651858.CD002277.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0140-6736(79)90823-7","article-title":"Long term effects of repeated plasma exchange in myasthenia gravis","volume":"1","author":"Newsom-Davis","year":"1979","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD002277.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jama.1986.03380100107031","article-title":"The utility of therapeutic plasmapheresis for neurological disorders","volume":"256","author":"NIH Consensus","year":"1986","journal-title":"The Journal of the American Medical Association"},{"issue":"24","key":"10.1002\/14651858.CD002277.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1001\/jama.1990.03450240091046","article-title":"Intravenous immunoglobulin: prevention and treatment of disease","volume":"264","author":"NIH Consensus","year":"1990","journal-title":"The Journal of the American Medical Association"},{"issue":"3","key":"10.1002\/14651858.CD002277.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0022-510X(83)90096-5","article-title":"Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients","volume":"58","author":"Oosterhuis","year":"1983","journal-title":"Journal of the Neurological Sciences"},{"issue":"6","key":"10.1002\/14651858.CD002277.pub4-BIB0039|cit39","first-page":"497","article-title":"Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients","volume":"38","author":"Osserman","year":"1971","journal-title":"Mount Sinai Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD002277.pub4-BIB0040|cit40","first-page":"413","article-title":"A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia","volume":"33","author":"Perez-Nellar","year":"2001","journal-title":"Revista de Neurologia"},{"issue":"8000","key":"10.1002\/14651858.CD002277.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0140-6736(76)91917-6","article-title":"Remission of myasthenia gravis following plasma exchange","volume":"2","author":"Pinching","year":"1976","journal-title":"Lancet"},{"issue":"9047","key":"10.1002\/14651858.CD002277.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome","volume":"349","author":"Plasma exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD002277.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.52.3.629","article-title":"Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis","volume":"52","author":"Qureshi","year":"1999","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD002277.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archneur.1984.04050180037013","article-title":"Chronic long interval plasma exchange in myasthenia gravis","volume":"41","author":"Rodnitzky","year":"1984","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD002277.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s004150050585","article-title":"Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis","volume":"247","author":"Sharshar","year":"2000","journal-title":"Journal of Neurology"},{"issue":"12","key":"10.1002\/14651858.CD002277.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double blind, randomized, placebo controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002277.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4414\/sanp.2007.01882","article-title":"Treatment of myasthenia gravis","volume":"158","author":"Toyka","year":"2007","journal-title":"Schweizer Archiv Fur Neurologie Und Psychiatrie"},{"issue":"2","key":"10.1002\/14651858.CD002277.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D","article-title":"The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders","volume":"20","author":"Mech\u00e9","year":"1997","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD002277.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","article-title":"Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets","volume":"2","author":"Vincent","year":"2003","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD002277.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1196\/annals.1405.005","article-title":"Clinical phenotype of muscle-specific tyrosine kinase antibody positive myasthenia gravis","volume":"1132","author":"Wolfe","year":"2008","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1","key":"10.1002\/14651858.CD002277.pub4-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002277.pub3","article-title":"Intravenous immunoglobulin for myasthenia gravis","author":"Gajdos","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD002277.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:06:02Z","timestamp":1733702762000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002277.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,12,12]]},"references-count":51,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2012,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002277.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,12]]}}}